Home>>Signaling Pathways>> Immunology/Inflammation>> NF-κB>>NF-κB Activation Inhibitor III

NF-κB Activation Inhibitor III (Synonyms: SM-7368)

Catalog No.GC11736

NF-κB Activation Inhibitor III is a potent NF-kB inhibitor that targets downstream of MAPK p38 activation. NF-κB Activation Inhibitor III inhibits TNF-α-induced MMP-9 upregulation. NF-κB Activation Inhibitor III can be used for the research of chemotherapies targeting TNF-α-mediated tumor invasion and metastasis .

Products are for research use only. Not for human use. We do not sell to patients.

NF-κB Activation Inhibitor III Chemical Structure

Cas No.: 380623-76-7

Size Price Stock Qty
5mg
$79.00
In stock
25mg
$260.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

NF-κB Activation Inhibitor III is a NF-κB inhibitor.

NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) is a protein complex controling transcription of DNA, cytokine production as well as cell survival. NF-κB is found in nearly all animal cell types and is involved in cellular responses to stimuli such as cytokines, stress, free radicals, heavy metals, and bacterial or viral antigens.

In vitro: Previous study found that NF-κB Activation Inhibitor III could inhibite TNF-a-induced MMP-9 upregulation in concentration-dependently and showed maximal activity at 10 μM. NF-κB Activation Inhibitor III also inhibited TNF-a-induced MMP-9 mRNA transcript accumulation and protein expression. It was also found that NF-κB Activation Inhibitor III strongly inhibited TNF-a-induced NF-jB activity but not AP-1 activity. In addition, NF-κB Activation Inhibitor III was able to strongly inhibit the TNF-a-induced invasion of HT1080 human fibrosarcoma cell line. These findings demonstrated that NF-κB Activation Inhibitor III was a synthetic compound inhibiting TNF-a-induced MMP-9 expression, and therefore NF-κB Activation Inhibitor III would be useful for the development of chemotherapy targeting TNF-a-mediated tumor invasion and metastasis [1]. NF-κB Activation Inhibitor III was used to disrupt NF-κB signaling to evaluate the role of syndecans in mediating extracellular matrix integrity [2].

In vivo: So far, there is no animal in vivo data reported.

Clinical trial: Up to now, NF-κB Activation Inhibitor III is still in the preclinical development stage.

References:
[1] H.  Y. Lee, K. S. Park, M. K. Kim, et al. A small compound that inhibits tumor necrosis factor-α-induced matrix metalloproteinase-9 upregulation. Biochemical and Biophysical Research Communications 336(2), 716-722 (2005).
[2] H.  Yang, H. Liu, X. Li, et al. TNF-α and TGF-β1 regulate Syndecan-4 expression in nucleus pulposus cells: Role of the mitogen-activated protein kinase and NF-κB pathways. Connect.Tissue Res. 56(4), 281-287 (2015).

Reviews

Review for NF-κB Activation Inhibitor III

Average Rating: 5 ★★★★★ (Based on Reviews and 21 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for NF-κB Activation Inhibitor III

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.